Leo Pharma Strengthens Dermatology Position With Second Eczema Win

 
• By Alaric DeArment

The company reported positive topline results from a second trial of its topical pan-JAK inhibitor, delgocitinib, in chronic hand eczema.

Leo announced positive topline Phase III results for its topical JAK inhibitor in chronic hand eczema • Source: Shutterstock

More from Clinical Trials

More from R&D